Hyperfine, Inc. (Nasdaq: HYPR), a groundbreaking medical technology company that has redefined brain imaging, has secured $17,500,000 in a recent funding round. The company is widely recognized for its Swoop® system, the world’s first FDA-cleared, portable, ultra-low-field magnetic resonance brain imaging system. This innovative device brings MR brain imaging within reach, capable of providing imaging at multiple points of care, having received initial U.S. Food and Drug Administration (FDA) clearance in 2020.
Hyperfine's core mission is to revolutionize patient care globally through transformational, accessible, and clinically relevant diagnostic imaging and data solutions. The Swoop® system is a portable ultra-low field magnetic resonance imaging device specifically designed to produce images that display the internal structure of the head. It is particularly useful in scenarios where a full diagnostic examination is not clinically practical, with images providing valuable information when interpreted by a trained physician.
This significant capital raise underscores investor confidence in Hyperfine's unique technology and its potential to enhance diagnostic imaging accessibility. The company plans to strategically deploy the $17.5 million to accelerate its growth initiatives, further expand its commercialization efforts for the Swoop® system, and continue investing in its research and development pipeline to enhance its offerings.
The investment positions Hyperfine to further advance its strategic objectives and broaden its global footprint. With this new capital, Hyperfine is set to continue its trajectory of innovation, aiming to make advanced brain imaging more accessible and contribute to improved patient outcomes worldwide through its pioneering diagnostic solutions.
